Expert Ratings For NewAmsterdam Pharma
Portfolio Pulse from Benzinga Insights
NewAmsterdam Pharma (NASDAQ:NAMS) has received mixed analyst ratings over the past three months, with a majority being somewhat bullish. Analysts have set a 12-month price target range of $31.00 to $37.00, with an average of $33.75, slightly up from the previous $33.00. The company shows strong revenue growth but faces challenges in profitability and asset utilization.
September 23, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NewAmsterdam Pharma has received mixed analyst ratings, with a majority being somewhat bullish. The 12-month price target average has increased to $33.75. The company shows strong revenue growth but faces challenges in profitability and asset utilization.
The increase in the average price target from $33.00 to $33.75 suggests a positive outlook from analysts, which could lead to a short-term price increase. However, the company's profitability challenges and asset utilization issues may temper this optimism. The mixed ratings, with a majority being somewhat bullish, indicate a cautious but positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100